Altimmune to Present Clinical Data from Pemvidutide at Upcoming EASL International Liver Congress™ 2024
Altimmune, a clinical-stage biopharmaceutical company, announced new data on pemvidutide, a novel peptide-based GLP-1/glucagon dual receptor agonist, at the EASL International Liver Congress™ 2024 in Milan. Pemvidutide is under development for treating obesity and metabolic dysfunction-associated steatohepatitis (MASH). The data highlights its anti-inflammatory and anti-fibrotic properties in subjects with metabolic dysfunction-associated steatotic liver disease (MASLD). Presentations include:
- Dr. Sarah Browne on metabolic dysfunction-associated steatohepatitis activity and fibrosis.
- Dr. Scot Roberts on plasma lipidomic profiling in subjects with obesity.
- Dr. Shaheen Tomah on noninvasive tests indicating histologic response in MASLD subjects.
These presentations will occur on June 5, 2024, at 8:30 am CEST, with posters displayed throughout the congress.
- Presentation of new data at a prestigious international congress.
- Highlighting anti-inflammatory and anti-fibrotic properties of pemvidutide.
- Focus on treating obesity and metabolic dysfunction-associated steatohepatitis (MASH).
- Clinical trial data indicating improvements in metabolic dysfunction-associated steatohepatitis activity and fibrosis.
- Plasma lipidomic profiling data showing impact on subjects with obesity.
- Noninvasive tests indicating histologic response improvements in MASLD subjects.
- No new financial data or revenue update provided.
- Potential risks and side effects of pemvidutide not discussed.
- No clear timeline for pemvidutide's market approval or commercialization.
- information on the scalability and production capabilities for pemvidutide.
GAITHERSBURG, Md., May 29, 2024 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that new data on the anti-inflammatory and anti-fibrotic properties of pemvidutide in subjects with metabolic dysfunction-associated steatotic liver disease (MASLD) will be presented at the EASL International Liver Congress™ 2024 in Milan, Italy. Pemvidutide is a novel, investigational, peptide-based GLP-1/glucagon dual receptor agonist in development for the treatment of obesity and metabolic dysfunction-associated steatohepatitis (MASH).
Details for the presentations are as follows:
| Title: | Pemvidutide, a glucagon-like peptide 1/glucagon dual receptor agonist, improves metabolic dysfunction-associated steatohepatitis activity and fibrosis in a clinical quantitative systems pharmacology model (abstract #2881) |
| Presenter: | Sarah Browne, M.D., Vice President, Clinical Development, Altimmune |
| Date/Time: | Wednesday, June 5, 2024, at 8:30 am CEST |
| Title: | Plasma lipidomic profiling of subjects with overweight or obesity following treatment with the glucagon-like peptide 1/glucagon dual receptor agonist pemvidutide: an investigation of lipid signatures associated with metabolic dysfunction-associated steatohepatitis (abstract #2985) |
| Presenter: | Scot Roberts, Ph.D., Chief Scientific Officer, Altimmune |
| Date/Time: | Wednesday, June 5, 2024, at 8:30 am CEST |
| Title: | Pemvidutide treatment is associated with improvement in noninvasive tests indicating greater likelihood of histologic response in subjects with metabolic dysfunction-associated steatotic liver disease: a 24-week, randomized, double-blind, placebo-controlled trial (abstract #3002) |
| Presenter: | Shaheen Tomah, M.D., Associate Director, Clinical Development, Altimmune |
| Date/Time: | Wednesday, June 5, 2024, at 8:30 am CEST |
These posters will be displayed during the four days of the congress and a copy will be accessible on the Events section of the Altimmune website.
About Pemvidutide
Pemvidutide is a novel, investigational, peptide-based GLP-1/glucagon dual receptor agonist in development for the treatment of obesity and MASH. Activation of the GLP-1 and glucagon receptors is believed to mimic the complementary effects of diet and exercise on weight loss, with GLP-1 suppressing appetite and glucagon increasing energy expenditure. Glucagon is also recognized as having direct effects on hepatic fat metabolism, which is believed to lead to rapid reductions in levels of liver fat and serum lipids. In clinical trials to-date, once-weekly pemvidutide has demonstrated compelling weight loss, robust reductions in triglycerides, LDL cholesterol, liver fat content and blood pressure. The U.S. FDA has granted Fast Track designation to pemvidutide for the treatment of MASH. Pemvidutide recently completed the MOMENTUM Phase 2 obesity trial and is being studied in the ongoing IMPACT Phase 2b MASH trial.
About Altimmune
Altimmune is a clinical-stage biopharmaceutical company focused on developing innovative next-generation peptide-based therapeutics. The Company is developing pemvidutide, a GLP-1/glucagon dual receptor agonist for the treatment of obesity and MASH. For more information, please visit www.altimmune.com.
Follow @Altimmune, Inc. on LinkedIn
Follow @AltimmuneInc on Twitter
Company Contact:
Richard Eisenstadt
Chief Financial Officer
Phone: 240-654-1450
ir@altimmune.com
Investor Contacts:
Lee Roth
Burns McClellan
Phone: 646-382-3403
lroth@burnsmc.com
Julia Weilman
Burns McClellan
Phone: 646-732-4443
jweilman@burnsmc.com
Media Contact:
Danielle Cantey
Inizio Evoke, Biotech
Phone: 619-826-4657
Danielle.cantey@inizioevoke.com
FAQ
What is pemvidutide?
When will Altimmune present data on pemvidutide?
What are the properties of pemvidutide?
What is Altimmune's stock symbol?
What clinical data will Altimmune present at EASL 2024?
